Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
Authors
Keywords
-
Journal
Nanomaterials
Volume 10, Issue 9, Pages 1674
Publisher
MDPI AG
Online
2020-08-26
DOI
10.3390/nano10091674
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cell membrane-camouflaged nanoparticles as drug carriers for cancer therapy
- (2020) Cheng-Hui Xu et al. Acta Biomaterialia
- A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
- (2020) Xuesai Zhang et al. MOLECULAR IMMUNOLOGY
- Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond
- (2020) Caterina Marchiò et al. SEMINARS IN CANCER BIOLOGY
- HER2 targeted biological macromolecule modified liposomes for improved efficacy of capecitabine in breast cancer
- (2020) Mantosh Kumar Singh et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
- (2020) A.C. Marques et al. JOURNAL OF CONTROLLED RELEASE
- Recent advances of antibody drug conjugates for clinical applications
- (2020) Pengxuan Zhao et al. Acta Pharmaceutica Sinica B
- Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling
- (2020) Ghmkin Hassan et al. MEDICAL HYPOTHESES
- Click Chemistry as a Tool for Cell Engineering and Drug Delivery
- (2019) Yukiya Takayama et al. MOLECULES
- Development of a kinetic antibody-dependent cellular cytotoxicity assay
- (2019) Lynn Kamen et al. JOURNAL OF IMMUNOLOGICAL METHODS
- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
- (2019) Gabriel Rinnerthaler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Click chemistry-mediated tumor-targeting of SN38-loaded nanoparticles using trastuzumab
- (2019) Jihye Yoo et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Trastuzumab-Modified Gold Nanoparticles Labeled with 211At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer
- (2019) Łucja Dziawer et al. Nanomaterials
- Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy
- (2019) Rossina Domínguez-Ríos et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
- (2019) Celia Nieto et al. Nanomaterials
- Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy
- (2019) Yongbing Sun et al. Asian Journal of Pharmaceutical Sciences
- Clinicopathologic factors associated with response to neoadjuvant anti-HER2-directed chemotherapy in HER2-positive breast cancer
- (2019) Jane L. Meisel et al. Clinical Breast Cancer
- Trastuzumab-Coated Nanoparticles Loaded With Docetaxel for Breast Cancer Therapy
- (2019) Xueyan Zhang et al. Dose-Response
- Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer
- (2019) Ana I. Matos et al. JOURNAL OF CONTROLLED RELEASE
- Passive and active targeting strategies in hybrid layered double hydroxides nanoparticles for tumor bioimaging and therapy
- (2019) Karina Nava Andrade et al. APPLIED CLAY SCIENCE
- Antibody conjugated onto surface modified magnetic nanoparticles for separation of HER2+ breast cancer cells
- (2019) Amir Hossein Haghighi et al. JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS
- Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy
- (2019) Sibi Raj et al. SEMINARS IN CANCER BIOLOGY
- Impact of conjugation strategies for targeting of antibodies in gold nanoparticles for ultrasensitive detection of 17β-estradiol
- (2019) Jairo Pinto Oliveira et al. Scientific Reports
- Neurotoxicity of antibodies in cancer therapy: A review
- (2019) Erika Horta et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
- (2019) Zhuyu Xu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Glyco-nanoparticles: New drug delivery systems in cancer therapy
- (2019) Haroon Khan et al. SEMINARS IN CANCER BIOLOGY
- The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer
- (2018) Kimberly Blackwell et al. Clinical Breast Cancer
- Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
- (2018) Lisa Belfiore et al. JOURNAL OF CONTROLLED RELEASE
- Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting
- (2018) Lucía Martínez-Jothar et al. JOURNAL OF CONTROLLED RELEASE
- Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumab-conjugated liposomes
- (2018) Mansour Amin et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Comparison of adsorption and conjugation of Herceptin on poly(lactic- co -glycolic acid) nanoparticles – Effect on cell internalization in breast cancer cells
- (2018) Jin-Seok Choi et al. Materials Science & Engineering C-Materials for Biological Applications
- HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
- (2018) Tetsushi Kubota et al. Nanomedicine-Nanotechnology Biology and Medicine
- Forming next-generation antibody–nanoparticle conjugates through the oriented installation of non-engineered antibody fragments
- (2018) Michelle K. Greene et al. Chemical Science
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Recent advances in applying nanotechnologies for cancer immunotherapy
- (2018) Reza Mahjub et al. JOURNAL OF CONTROLLED RELEASE
- Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy
- (2018) Abhishesh Kumar Mehata et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy
- (2017) Hanh Thuy Nguyen et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Targeted cancer therapy through antibody fragments-decorated nanomedicines
- (2017) Abbas Alibakhshi et al. JOURNAL OF CONTROLLED RELEASE
- Hydrophobic lapatinib encapsulated dextran-chitosan nanoparticles using a toxic solvent free method: fabrication, release property & in vitro anti-cancer activity
- (2017) Rezvan Mobasseri et al. Materials Science & Engineering C-Materials for Biological Applications
- Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering
- (2017) Maximillian T. W. Lee et al. Chemical Science
- Pyridazinediones deliver potent, stable, targeted and efficacious antibody–drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody
- (2017) Eifion Robinson et al. RSC Advances
- Trastuzumab-decorated nanoparticles for in vitro and in vivo tumor-targeting hyperthermia of HER2+ breast cancer
- (2017) Javad Hamzehalipour Almaki et al. Journal of Materials Chemistry B
- Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models
- (2017) Outi Keinänen et al. EJNMMI Research
- HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
- (2016) Kathy Miller et al. BMC CANCER
- An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
- (2016) Hongwen Li et al. CANCER BIOLOGY & THERAPY
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
- (2016) Christopher W. Espelin et al. CANCER RESEARCH
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- HER2-targeted antibody drug conjugates for ovarian cancer therapy
- (2016) Jing Jiang et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells
- (2016) Kongtong Yu et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry
- (2016) Padma Akkapeddi et al. Chemical Science
- A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity
- (2015) Xuejing Yao et al. BREAST CANCER RESEARCH AND TREATMENT
- Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody–drug conjugate (ADC)
- (2015) João P. M. Nunes et al. CHEMICAL COMMUNICATIONS
- Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer
- (2015) Xu Wan et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Peptide Aptamers: Development and Applications
- (2015) Sergey Reverdatto et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Tumor targeting using polyamidoamine dendrimer–cisplatin nanoparticles functionalized with diglycolamic acid and herceptin
- (2015) Akila Kesavan et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery
- (2015) Zilan Zhou et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism
- (2014) Li Zhang et al. ACTA PHARMACOLOGICA SINICA
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trastuzumab-Conjugated Liposome-Coated Fluorescent Magnetic Nanoparticles to Target Breast Cancer
- (2014) Mijung Jang et al. KOREAN JOURNAL OF RADIOLOGY
- Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging
- (2014) Felix F. Schumacher et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
- (2013) W. J. Gradishar ANNALS OF ONCOLOGY
- Aptamers: multifunctional molecules for biomedical research
- (2013) Jayeeta Banerjee et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Current trends in the use of liposomes for tumor targeting
- (2013) Pranali P Deshpande et al. Nanomedicine
- Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds
- (2013) Chih-Sheng Chiang et al. Nanomedicine-Nanotechnology Biology and Medicine
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- The tumor microenvironment is a dominant force in multidrug resistance
- (2012) Ana Luísa Correia et al. DRUG RESISTANCE UPDATES
- Trastuzumab decorated methotrexate–human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells
- (2012) Azade Taheri et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Biomedical Applications of Tetrazine Cycloadditions
- (2011) Neal K. Devaraj et al. ACCOUNTS OF CHEMICAL RESEARCH
- Antibody-DM1 conjugates as cancer therapeutics
- (2011) Manu Lopus CANCER LETTERS
- The synergistic effect of herceptin and docetaxel in polylactide-D- α -tocopheryl polyethylene glycol succinate (PLA-TPGS) nanoparticles
- (2011) Yutao Liu et al. JOURNAL OF CONTROLLED RELEASE
- Albumin-based nanoparticles as potential controlled release drug delivery systems
- (2011) Ahmed O. Elzoghby et al. JOURNAL OF CONTROLLED RELEASE
- Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy
- (2011) Geetanjali Arya et al. Nanomedicine-Nanotechnology Biology and Medicine
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Gold nanoparticle platforms as drug and biomacromolecule delivery systems
- (2010) Bradley Duncan et al. JOURNAL OF CONTROLLED RELEASE
- HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches
- (2010) Miriam Colombo et al. PHARMACOLOGICAL RESEARCH
- Lapatinib: A competitor or companion to trastuzumab?
- (2009) D. Collins et al. CANCER TREATMENT REVIEWS
- Polysaccharides-based nanoparticles as drug delivery systems
- (2008) Zonghua Liu et al. ADVANCED DRUG DELIVERY REVIEWS
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties
- (2008) S Kumar et al. Nature Protocols
- Click Chemistry, A Powerful Tool for Pharmaceutical Sciences
- (2008) Christopher D. Hein et al. PHARMACEUTICAL RESEARCH
- Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer
- (2007) Bingfeng Sun et al. BIOMATERIALS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now